NO20022187D0 - Fremgangsmåte for behandling og forebygging av neurodegenerative forstyrrelser - Google Patents

Fremgangsmåte for behandling og forebygging av neurodegenerative forstyrrelser

Info

Publication number
NO20022187D0
NO20022187D0 NO20022187A NO20022187A NO20022187D0 NO 20022187 D0 NO20022187 D0 NO 20022187D0 NO 20022187 A NO20022187 A NO 20022187A NO 20022187 A NO20022187 A NO 20022187A NO 20022187 D0 NO20022187 D0 NO 20022187D0
Authority
NO
Norway
Prior art keywords
treating
neurodegenerative disorders
preventing neurodegenerative
adatanserin
disorders
Prior art date
Application number
NO20022187A
Other languages
English (en)
Other versions
NO322371B1 (no
NO20022187L (no
Inventor
Magid Abdel-Megid Abou-Gharbia
James Edward Barrett
Jr Wayne Everett Childers
John Allen Moyer
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20022187L publication Critical patent/NO20022187L/no
Publication of NO20022187D0 publication Critical patent/NO20022187D0/no
Publication of NO322371B1 publication Critical patent/NO322371B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Processing Of Meat And Fish (AREA)
NO20022187A 1999-11-12 2002-05-07 Anvendelse av adatanserin for fremstilling av et medikament NO322371B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43921999A 1999-11-12 1999-11-12
PCT/US2000/030973 WO2001034136A2 (en) 1999-11-12 2000-11-10 Use of adatanserin for the treatment of neurodegenerative conditions

Publications (3)

Publication Number Publication Date
NO20022187L NO20022187L (no) 2002-05-07
NO20022187D0 true NO20022187D0 (no) 2002-05-07
NO322371B1 NO322371B1 (no) 2006-09-25

Family

ID=23743796

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022187A NO322371B1 (no) 1999-11-12 2002-05-07 Anvendelse av adatanserin for fremstilling av et medikament

Country Status (22)

Country Link
EP (2) EP1242089B1 (no)
JP (1) JP2003513915A (no)
KR (1) KR100757226B1 (no)
CN (1) CN100469368C (no)
AT (1) ATE291919T1 (no)
AU (1) AU773733B2 (no)
BR (1) BR0015523A (no)
CA (1) CA2390797A1 (no)
CZ (1) CZ298535B6 (no)
DE (1) DE60019166T2 (no)
EA (1) EA006099B1 (no)
ES (1) ES2235998T3 (no)
HK (1) HK1046505B (no)
HU (1) HUP0301847A3 (no)
IL (1) IL149264A0 (no)
MX (1) MXPA02004654A (no)
NO (1) NO322371B1 (no)
NZ (1) NZ518814A (no)
PL (1) PL355014A1 (no)
PT (1) PT1242089E (no)
WO (1) WO2001034136A2 (no)
ZA (1) ZA200204682B (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298535B6 (cs) * 1999-11-12 2007-10-31 Wyeth Farmaceutický prostredek
WO2009082268A2 (ru) 2007-12-21 2009-07-02 Alla Chem, Llc ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441961A (en) * 1992-08-27 1995-08-15 Eli Lilly And Company Substituted cyclo or bicycloalkylamides of (8β)-6-(substituted) ergolines
US5877173A (en) * 1996-08-28 1999-03-02 Washington University Preventing neuronal degeneration in Alzheimer's disease
US5902815A (en) * 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
CZ298535B6 (cs) * 1999-11-12 2007-10-31 Wyeth Farmaceutický prostredek

Also Published As

Publication number Publication date
HUP0301847A3 (en) 2004-01-28
DE60019166D1 (de) 2005-05-04
IL149264A0 (en) 2002-11-10
CZ20021629A3 (cs) 2003-06-18
EA006099B1 (ru) 2005-08-25
KR100757226B1 (ko) 2007-09-11
HK1046505B (zh) 2005-06-03
WO2001034136A3 (en) 2002-03-21
HUP0301847A2 (hu) 2003-09-29
CN100469368C (zh) 2009-03-18
CA2390797A1 (en) 2001-05-17
EP1547597A3 (en) 2006-09-27
CZ298535B6 (cs) 2007-10-31
NO322371B1 (no) 2006-09-25
PL355014A1 (en) 2004-03-22
MXPA02004654A (es) 2004-09-10
AU773733B2 (en) 2004-06-03
ATE291919T1 (de) 2005-04-15
JP2003513915A (ja) 2003-04-15
ZA200204682B (en) 2003-09-11
CN1390128A (zh) 2003-01-08
EP1242089A2 (en) 2002-09-25
ES2235998T3 (es) 2005-07-16
HK1046505A1 (en) 2003-01-17
EP1242089B1 (en) 2005-03-30
BR0015523A (pt) 2002-10-22
DE60019166T2 (de) 2006-05-11
NO20022187L (no) 2002-05-07
EP1547597A2 (en) 2005-06-29
WO2001034136A2 (en) 2001-05-17
NZ518814A (en) 2005-08-26
EA200200559A1 (ru) 2002-12-26
KR20020073132A (ko) 2002-09-19
PT1242089E (pt) 2005-08-31
AU1656701A (en) 2001-06-06

Similar Documents

Publication Publication Date Title
DK0713701T3 (da) 2-Brommelatonin til behandling af søvnforstyrrelser
DK1525219T3 (da) GLP-1 og fremgangsm der til behandling af diabetes
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
BR0115166A (pt) Combinações de drogas (por exemplo, cloropromazina e pentamidina) para o tratamento de distúrbios neoplásticos
FI19991893A (fi) Säädellysti budesonidia vapauttava oraalisesti annettava koostumus ja budesonidin käyttö
FR2712811B1 (fr) Procédé pour lutter contre l'adiposite et compositions utilisables à cet effet.
PT1039900E (pt) Agentes terapeuticos
RU94002133A (ru) 6-хлор-5-фтор-3-(2-теноил)-2-оксиндол-1-карбоксамид как аналгезирующее и противовоспалительное средство
NO20022187D0 (no) Fremgangsmåte for behandling og forebygging av neurodegenerative forstyrrelser
NO971453D0 (no) Anvendelse av bradykinin-antagonister for fremstilling av legemidler for behandling av kroniske fibrogenetiske og akutte leversykdommer
BR9708037A (pt) Método para o tratamento de abuso de substância
EE04951B1 (et) R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine uneh„irete raviks
NO960866D0 (no) Fremgangsmåte til behandling av leversykdom og lignende indikasjoner med vasodilaterende midler
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
RU94013606A (ru) Гемостимулятор
WO2003059334A3 (en) Gemcitabine in the treatment of smallpox
RU95117774A (ru) Способ лечения хронических воспалительных заболеваний верхних дыхательных путей
RU93050675A (ru) Способ коррекции психофизиологического состояния человека
RU97110384A (ru) Способ лечения вибрационной болезни
RU2000106699A (ru) Способ лечения заболеваний методом настройки биоритмов организма
RU94034142A (ru) Способ немедикаментозного лечения больных с психологическо-вегетативными расстройствами
RU2003133629A (ru) Способ лечения острых ангинозных болей при остром коронарном синдроме
NO941314L (no) Anordning for transdermal administrering av melatonin
RU93014293A (ru) Способ лечения хронического бронхита

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees